On the morning of September 15th, CStone Pharmaceuticals (02616), a subsidiary of Zhongzheng Intelligent Finance , announced that its autoimmune and inflammatory drug candidate, CS2015 (OX40L/TSLP bispecific antibody), has been selected for presentation at the 2025 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6th to 10th.　　CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. By dually inhibiting key regulators of Th2-mediated inflammatory responses, it provides a new treatment strategy for type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on drug research and development in key disease areas such as oncology, autoimmunity, and inflammation. Since its establishment, it has successfully launched four innovative drugs., and obtained approval for 16 new drug applications. The current R&D pipeline includes 16 drug candidates, including antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.

https://finance.eastmoney.com/a/202509153513564779.html